Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study.
Journal
HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
21
08
2019
revised:
04
10
2019
accepted:
24
10
2019
entrez:
25
1
2020
pubmed:
25
1
2020
medline:
25
1
2020
Statut:
epublish
Résumé
Invasive fungal diseases (IFDs) remain a major clinical issue in patients with hematological malignancies (HMs). To confirm the efficacy and safety of the new azole isavuconazole (ISV) in a clinical care setting, we planned a multicenter retrospective study; we collected data on all possible/probable/proven IFDs in patients with HMs treated with ISV in 17 centers. Between July 2016 and November 2018, 128 patients were enrolled, and 122 were fully evaluable. ISV was employed as the 1
Identifiants
pubmed: 31976489
doi: 10.1097/HS9.0000000000000320
pii: HemaSphere-2019-0168
pmc: PMC6924559
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e320Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Leuk Res. 2014 Apr;38(4):469-74
pubmed: 24534569
Clin Infect Dis. 2020 Feb 14;70(5):723-730
pubmed: 30958538
Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38
pubmed: 29544767
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3025-31
pubmed: 26953193
Mycoses. 2019 Jun;62(6):534-541
pubmed: 30851214
Haematologica. 2008 Jan;93(1):159-60
pubmed: 18166809
Clin Infect Dis. 2016 Dec 1;63(11):1529-1530
pubmed: 27553376
Antimicrob Agents Chemother. 2019 May 24;63(6):
pubmed: 30962330
Antimicrob Agents Chemother. 2015 Apr;59(4):2078-85
pubmed: 25624327
J Antimicrob Chemother. 2017 Mar 1;72(suppl_1):i2-i4
pubmed: 28355461
Biol Blood Marrow Transplant. 2014 Jun;20(6):872-80
pubmed: 24631738
Med Mycol. 2019 Apr 1;57(Supplement_2):S127-S137
pubmed: 30816979
Clin Infect Dis. 2018 Oct 30;67(10):1610-1613
pubmed: 29771293
Mycoses. 2019 Aug;62(8):665-672
pubmed: 31050373
Scand J Infect Dis. 2009;41(6-7):483-90
pubmed: 19347772
Clin Microbiol Infect. 2013 Aug;19(8):757-62
pubmed: 23279327
Med Mycol. 2017 Jan 1;55(1):82-86
pubmed: 27915304
Haematologica. 2017 Mar;102(3):433-444
pubmed: 28011902
Ther Clin Risk Manag. 2016 Aug 03;12:1197-206
pubmed: 27536124
Mycoses. 2019 Jan;62(1):81-86
pubmed: 30230043
Haematologica. 2011 Feb;96(2):337-41
pubmed: 21071502
Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):991-7
pubmed: 21909650
Clin Infect Dis. 2018 Jan 6;66(1):140-148
pubmed: 29029010
Mycoses. 2019 Sep;62(9):716-729
pubmed: 31254420
Lancet Infect Dis. 2016 Jul;16(7):828-837
pubmed: 26969258
Lancet. 2016 Feb 20;387(10020):760-9
pubmed: 26684607
Int J Clin Pharmacol Ther. 2016 Aug;54(8):572-80
pubmed: 27345284
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
pubmed: 18462102
Clin Infect Dis. 2019 Oct 15;69(9):1624-1627
pubmed: 30861066